Navigation Links
Accelerated Development of New Treatment for Multi Drug-Resistant Tuberculosis: TB Alliance and Tibotec Announce Unique Partnership to Develop TMC207
Date:6/17/2009

SEATTLE, June 17 /PRNewswire/ --

    When:    Wednesday, June 17, 2009, 10:30am Eastern (9:30am Central; 8:30am
             Mountain; 7:30am Pacific)

    Dial-in: 1-877-879-6184 (toll-free)
             1-719-325-4759 (local access)
             Conference Title: TB Alliance/Tibotec Briefing
             Participant passcode: 2895940

    Where:   Pacific Health Summit
             Bell Harbor International Conference Center
             Pacific Board Room
             Seattle, Washington

Today at the Pacific Health Summit, the Global Alliance for TB Drug Development (TB Alliance) and Tibotec announced a unique partnership to accelerate multi drug-resistant tuberculosis (MDR-TB) drug development. The two organizations will work together to develop TMC207, which is currently being studied in Phase II clinical trials in patients with MDR-TB. TMC207 could become the first tuberculosis treatment in 40 years to feature a new mechanism of action against the disease. Novel drugs are urgently needed to fight deadly MDR-TB, which caused an estimated 130,000 deaths worldwide in 2007.

    Speakers:
        Mel Spigelman, M.D., president and CEO, Global Alliance for TB Drug
         Development
        Paul Stoffels, M.D., Global Head Pharmaceutical Research and
         Development, Johnson & Johnson
        Jaime N. Bayona, M.D., M.P.H., director, Socios En Salud (Partners
         In Health) Lima, Peru

Background:

Interim data from an ongoing Phase II study of TMC207 were recently published in the New England Journal of Medicine. In the placebo-controlled study of 47 patients with MDR-TB, it was found that 48 percent of patients receiving TMC207 in combination with standard treatment converted to negative sputum culture after eight weeks compared with 9 percent of those who received placebo and standard treatment. The safety and efficacy of TMC207 will be further evaluated in Phase 3 clinical trials.

Tuberculosis kills one person approximately every twenty seconds. MDR-TB, which is characterized by resistance to at least two of the most powerful medicines in today's standard, four-drug regimen for drug-susceptible TB, is of particular concern given the rapid rise in the number of cases throughout the world and the difficulties in treating it. There were an estimated 510,000 incident cases and 130,000 fatalities due to MDR-TB in 2007. Drug-resistant strains are extremely difficult and expensive to treat and novel drugs are urgently needed to fight these deadly strains.

Dr. Mel Spigelman, the president and CEO of the TB Alliance, and Dr. Paul Stoffels, Global Head Pharmaceutical Research and Development, Johnson & Johnson, will discuss this landmark partnership. Dr. Jaime Bayona, M.D., director and founder of Socios En Salud, Lima, Peru, was integral in helping Paul Famer, M.D., Ph.D., establish a pilot MDR-TB treatment program clinic in Peru. As an authority on approaches to the control of MDR-TB, Dr. Bayona can speak first-hand to the urgent need for novel treatments for MDR-TB.

Contact:

Joanna Breitstein, Global Alliance for TB Drug Development, +1 917-361-0683, joanna.breitstein@tballiance.org

Karen Manson, Tibotec, +32-479-89-47-99, kmanson@its.jnj.com

Sarah Bailey, GCI Health, +1 212-537-8291, sarah.bailey@gcihealth.com


'/>"/>
SOURCE TB Alliance; Tibotec
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Scripps Florida scientists devise accelerated method to determine infectious prion strains
2. Adoption of Consumer-Driven Health Plans Accelerated by Recession
3. Academy of Lymphatic Studies Announces Accelerated Hybrid Online Program
4. Effects of smoking linked to accelerated aging protein
5. UC San Diego engineers develop novel method for accelerated bone growth
6. The Foundation for Accelerated Vascular Research Grants $150,000 Wylie Scholar Award for Blood Vessel Research
7. Accelerated Cure Project for Multiple Sclerosis is One Thousand Steps Closer to a Cure for MS
8. American Stock Exchange Lists Merrill Lynchs Accelerated Return Notes Linked to the Amex Health Care Select Sector Index
9. DuPont Chief Financial Officer Reviews Companys Accelerated Growth Plan
10. Adult stem cell changes underlie rare genetic disease associated with accelerated aging
11. Accelerated head growth can predict autism before behavioral symptoms start
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: